Filana Therapeutics (FLNA) vs NextCure (NXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
NextCure (NXTC) has outperformed Filana Therapeutics (FLNA) over the past year, losing 38.6% versus a loss of 77.7%. Over five years, NXTC leads with a -91.1% price change compared with -98.9% for FLNA. Filana Therapeutics is the larger company by market cap ($32.3 million vs $29.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FLNA | NXTC |
|---|---|---|
| Share price | $0.6413 | $6.45 |
| Market cap | $32.26M | $29.53M |
| 1-day change | +14.52% | -4.87% |
| YTD return | -67.61% | -54.55% |
| 1-year return | -77.66% | -38.63% |
| 5-year return | -98.85% | -91.07% |
| EPS (TTM) | $-0.87 | $-6.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-90.97M | $-55.84M |
| 52-week high | $3.45 | $15.74 |
| 52-week low | $0.39 | $1.55 |
| Distance from 52-week high | -81.41% | -59.02% |
| Analyst consensus | none | none |
| Avg. price target upside | +913.57% | +210.08% |
| Average volume | 2.09M | 79.46K |
| Shares outstanding | 50.30M | 4.58M |
| Employees | 17 | 40 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NXTC has outperformed FLNA by 39.0 percentage points over the past year.
About Filana Therapeutics
FLNA stock →Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About NextCure
NXTC stock →NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees
FLNA vs NXTC FAQ
Which is bigger, Filana Therapeutics or NextCure?
Filana Therapeutics (FLNA) is larger, with a market capitalization of $32.26M compared with $29.53M for NextCure (NXTC).
Which stock has performed better over the past year, FLNA or NXTC?
NXTC returned -38.63% over the past 12 months, compared with -77.66% for FLNA (price return, excluding dividends). Past performance does not predict future results.
Are Filana Therapeutics and NextCure in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.